We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
- Authors
Niikura, Naoki; Yamanaka, Takashi; Nomura, Hironori; Shiraishi, Kazuhiro; Kusama, Hiroki; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Kiga, Yoko; Izutani, Tadahiro; Shiosakai, Kazuhito; Tsurutani, Junji
- Abstract
Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM. Data were analyzed for 104 patients administered T-DXd. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), intracranial (IC)-ORR, and IC-PFS were evaluated. ORR by investigator assessment was 55.7% (total population). Median PFS was 16.1 months; 12-month OS rate was 74.9% (total population). Median time-to-treatment failure was 9.7 months. In 51 patients with BM imaging, IC-ORR and median IC-PFS by independent central review were 62.7% and 16.1 months, respectively. In 19 LMC patients, 12-month PFS and OS rates were 60.7% and 87.1%, respectively. T-DXd showed effectiveness regarding IC-ORR, IC-PFS, PFS, and OS in breast cancer patients with BM/active BM, and sustained systemic and central nervous system disease control in LMC patients. Trial Registration: UMIN000044995.
- Subjects
HER2 positive breast cancer; MENINGEAL cancer; EPIDERMAL growth factor receptors; TRASTUZUMAB; CENTRAL nervous system diseases; CANCER patients
- Publication
NPJ Breast Cancer, 2023, Vol 9, Issue 1, p1
- ISSN
2374-4677
- Publication type
Article
- DOI
10.1038/s41523-023-00584-5